National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 40775 [2017-18121]
Download as PDF
<![CDATA[
40775
Federal Register / Vol. 82, No. 165 / Monday, August 28, 2017 / Notices
There will be a final report that is
thematically organized and describes
key findings and strategic
recommendations for Region VIII
OASH/OWH to consider supporting
future evidence-based program
development and implementation,
policy recommendations, and future
research.
Likely Respondents: Data for this
assessment will be collected through
three mechanisms—a survey of women
living in the assessment geography,
focus groups with a cross-section of
women and other key groups living in
the assessment geography, key leaders
and stakeholders across a variety of
governmental and non-governmental
sectors.
The total annual burden hours
estimated for this ICR are summarized
in the table below.
TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS
Number of
respondents
Form name
Number of
responses per
respondent
Average
burden per
response
(in hours)
Total burden
hours
Community Survey ..........................................................................................
Focus Groups ..................................................................................................
Interviews .........................................................................................................
500
240
40
1
1
1
15/60
90/60
60/60
125
360
40
Total ..........................................................................................................
780
1
40.4/60
525
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Terry S. Clark,
Asst Information Collection Clearance
Officer.
[FR Doc. 2017–18117 Filed 8–25–17; 8:45 am]
BILLING CODE 4150–33–P
Dated: August 22, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2017–18121 Filed 8–25–17; 8:45 am]
National Institutes of Health
BILLING CODE 4140–01–P
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel NIAID Peer Review Meeting.
Date: September 20–21, 2017.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892,
(Telephone Conference Call).
Contact Person: Kelly Y. Poe, Ph.D.,
Scientific Review Program, Division of
Extramural Activities, Room 3F40B, National
Institutes of Health, NIAID, 5601 Fishers
Lane, MSC 9823, Bethesda, MD 20892–9823,
(240) 669–5036, poeky@mail.nih.gov.
VerDate Sep<11>2014
18:45 Aug 25, 2017
Jkt 241001
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Chris Kornak, 240–627–3705,
Chris.Kornak@nih.gov. Licensing
information and copies of the U.S.
patent applications listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel.
SUMMARY:
PO 00000
Frm 00032
Fmt 4703
HIV Targets CD62L on Central Memory
T Cells Through Viral Envelope
Glycans for Adhesion and Induces
Selectin Shedding for Viral Release
Description of Technology
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
AGENCY:
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Sfmt 4703
Despite the success of anti-retroviral
therapy in controlling HIV in infected
individuals, treatment is less effective at
eliminating HIV viral reservoirs. The
nature of HIV reservoirs and the factors
controlling their size and release are a
major research focus for achieving a
cure for HIV/AIDS.
NIAID researchers have identified Lselectin/CD62L as a new target for
treating HIV by inhibiting viral release
from infected cells. They found that
shedding of CD62L on T cells is
required for the efficient release of HIV
virus from infected cells. Further, they
have shown that inhibition of CD62L
shedding dramatically reduced HIV–1
infection and viral release from both
viremic and aviremic CD4+ T cells.
Therefore, inhibitors for CD62L
sheddase can function as an anti-HIV
treatment that may be effective alone or
in combination with existing
therapeutics.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications
• New target for HIV therapeutic
development.
E:\FR\FM\28AUN1.SGM
28AUN1
]]>Agencies
[Federal Register Volume 82, Number 165 (Monday, August 28, 2017)]
[Notices]
[Page 40775]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-18121]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The contract proposals and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel NIAID Peer Review Meeting.
Date: September 20-21, 2017.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, 5601 Fishers Lane,
Rockville, MD 20892, (Telephone Conference Call).
Contact Person: Kelly Y. Poe, Ph.D., Scientific Review Program,
Division of Extramural Activities, Room 3F40B, National Institutes
of Health, NIAID, 5601 Fishers Lane, MSC 9823, Bethesda, MD 20892-
9823, (240) 669-5036, poeky@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: August 22, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-18121 Filed 8-25-17; 8:45 am]
BILLING CODE 4140-01-P
